全文获取类型
收费全文 | 857705篇 |
免费 | 71476篇 |
国内免费 | 1831篇 |
专业分类
耳鼻咽喉 | 12796篇 |
儿科学 | 24602篇 |
妇产科学 | 25091篇 |
基础医学 | 123636篇 |
口腔科学 | 25457篇 |
临床医学 | 74968篇 |
内科学 | 163392篇 |
皮肤病学 | 16955篇 |
神经病学 | 69832篇 |
特种医学 | 35158篇 |
外国民族医学 | 171篇 |
外科学 | 135797篇 |
综合类 | 24585篇 |
现状与发展 | 2篇 |
一般理论 | 263篇 |
预防医学 | 66527篇 |
眼科学 | 20486篇 |
药学 | 64644篇 |
中国医学 | 1597篇 |
肿瘤学 | 45053篇 |
出版年
2018年 | 7331篇 |
2015年 | 7722篇 |
2014年 | 11104篇 |
2013年 | 16777篇 |
2012年 | 22712篇 |
2011年 | 23825篇 |
2010年 | 13859篇 |
2009年 | 13058篇 |
2008年 | 22564篇 |
2007年 | 24613篇 |
2006年 | 24488篇 |
2005年 | 24137篇 |
2004年 | 23696篇 |
2003年 | 22828篇 |
2002年 | 21922篇 |
2001年 | 35823篇 |
2000年 | 36464篇 |
1999年 | 30895篇 |
1998年 | 9219篇 |
1997年 | 8494篇 |
1996年 | 7809篇 |
1995年 | 7936篇 |
1994年 | 7658篇 |
1992年 | 26613篇 |
1991年 | 26093篇 |
1990年 | 25605篇 |
1989年 | 24660篇 |
1988年 | 23197篇 |
1987年 | 22858篇 |
1986年 | 21723篇 |
1985年 | 21087篇 |
1984年 | 16353篇 |
1983年 | 13950篇 |
1982年 | 8822篇 |
1981年 | 8157篇 |
1980年 | 7625篇 |
1979年 | 16689篇 |
1978年 | 12073篇 |
1977年 | 10136篇 |
1976年 | 9291篇 |
1975年 | 10108篇 |
1974年 | 12614篇 |
1973年 | 12117篇 |
1972年 | 11523篇 |
1971年 | 10668篇 |
1970年 | 10194篇 |
1969年 | 9894篇 |
1968年 | 8890篇 |
1967年 | 8211篇 |
1966年 | 7640篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Phoebe Hammer Kevin White Stephanie Mengden Vessy Korcheva Philipp W. Raess 《Journal of cutaneous pathology》2019,46(5):343-346
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances. 相似文献
12.
13.
14.
Robert C. Lynall J. Troy Blackburn Kevin M. Guskiewicz Stephen W. Marshall Prudence Plummer Jason P. Mihalik 《Journal of Science and Medicine in Sport》2019,22(5):503-508
Objectives
Despite evidence for increased musculoskeletal injury after concussion recovery, there is a lack of dynamic balance assessments that could inform management and research into this increased injury risk post-concussion. Our purpose was to identify tandem gait dynamic balance deficits in recreational athletes with a concussion history within the past 18-months compared to matched controls.Design
Cross-sectional, laboratory study.Methods
Fifteen participants with a concussion history (age: 19.7 ± 0.9 years; 9 females; median time since concussion 126 days, range 28–432 days), and 15 matched controls (19.7 ± 1.6 years; 9 females) with no recent concussion history participated. We measured center-of-pressure (COP) outcomes (velocity, path length, speed, dual-task cost) under 4 tandem gait conditions: (1) tandem gait, (2) tandem gait, eyes closed, (3) tandem gait, eyes open, cognitive distraction, and (4) tandem gait, eyes closed, cognitive distraction.Results
The concussion history group demonstrated slower tandem gait velocity compared to the control group (4.0 cm/s difference), thus velocity was used as a covariate when analyzing COP path length and speed. The concussion history group (23.5%) demonstrated greater COP speed dual-task cost than the control group (16.3%) during the eyes closed dual-task condition. No other comparisons were statistically significant.Conclusions
There may be subtle dynamic balance differences during tandem gait that are detectable after return-to-activity following concussion, but the clinical significance of these findings is unclear. Longitudinal investigations should identify acute movement deficits in varying visual and cognitive scenarios after concussion in comparison with recovery on traditional concussion assessment tools while also recording musculoskeletal injury outcomes. 相似文献15.
16.
Samir Gupta MD MDCS AGAF Balambal Bharti MBBS MPH PhD Dennis J. Ahnen MD Daniel D. Buchanan PhD Iona C. Cheng PhD MPH Michelle Cotterchio PhD Jane C. Figueiredo PhD Steven J. Gallinger MD MSc Robert W. Haile DrPH MPH Mark A. Jenkins PhD Noralane M. Lindor MD Finlay A. Macrae MD AGAF Loïc Le Marchand MD PhD Polly A. Newcomb PhD MPH Stephen N. Thibodeau PhD Aung Ko Win MBBS MPH PhD Maria Elena Martinez PhD 《Cancer》2020,126(13):3013-3020
17.
Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population 下载免费PDF全文
Partha S RoyTomar NyoduMunlima HazarikaB J SaikiaC BhuyanAmit InamdarC W NyutheB BorthakurJ D Sharma 《Asian Pacific journal of cancer prevention》2019,20(4):1139-1145
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients. 相似文献
18.
19.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献20.